.

Forendo Pharma Successfully Completes Phase 1

Turku, Finland, March 3rd, 2021 – Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women's health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzymetargeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo's therapeutic concept.

Rejuvenate Biomed Secures EUR 3.2M

Heusden-Zolder, Belgium, 2nd March 2021 – Rejuvenate Biomed NV ("Rejuvenate"), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round.

CatalYm: Board Changes

Munich, Germany, March 1st 2021 – CatalYm GmbH, Announces Key Management and Board Changes:

  • Dr. Manfred Ruediger steps down as Chief Executive Officer of CatalYm
  • Dr. John Haurum succeeds Dr. Holger Reithinger as Chairman of the Supervisory Board

SWORD Health Raises $25 Million in Series B

NEW YORK, 2021 – SWORD Health, the world's fastest growing virtual musculoskeletal (MSK) care provider, has raised a $25 million financing round, bringing SWORD's cumulative fundraising to $50 million. The round was led by Todd Cozzens, Managing Partner at Transformation Capital and former healthcare investor at Sequoia Capital.

CatalYm: Clinical Trial with GDF-15

Munich, Germany, January 28th, 2021 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry into the tumor microenvironment.

OncoDNA wins Biotech Award

Gosselies, 27th November 2020 – Already celebrated by Deloitte's Technology Fast50 in 2015 and 2018, OncoDNA is thrilled to announce that it has received this year's award in the biotechnology and pharmaceutical category.

DEARhealth wins AI award!

On November 24th 2020, 21 winners of the Computable Awards 2020 were announced during a live broadcast in the Scala Theater at Jaarbeurs in Utrecht. For the first time, this year also included the Dutch Applied AI Award, in collaboration with Podcast "De Dataloog" and the Amsterdam University of Applied Science (HvA). Our very own Katinka de Korte was invited as a guest and found herself happily surprised when she was handed this brand new award for DEARhealth!

CatalYm raises EUR50 million

Munich, Germany, November 10th, 2020: CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round.

UCLA Health App: Global Business

Five years ago, this publication told you about DEARhealth, a health care platform from UCLA that grew into a business. A lot has happened in the past five years: The digital health company, founded by Drs. Daniel Hommes and Eric Esrailian, UCLA professors of medicine, offers a provider platform and patient app that helps manage chronic conditions, improve patient outcomes, and lower associated health costs.

Topas Therapeutics raises €22 Million

Hamburg, October 19th, 2020: Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a €22 million (~$26 million) Series B financing round. New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas' existing investors.

.

xxnoxx_zaehler